New in vitro co-culture model study published with citrus flavonoid extract MicrobiomeX®

Maastricht, Netherlands, April 21st, 2022

Press release
British Journal of Nutrition has recently published a new in vitro co-culture model study with a citrus flavonoid extract MicrobiomeX® and its metabolites, hesperetin and naringenin. The novel publication suggests that these citrus flavonoids, as well as their metabolites, may reduce intestinal inflammation.


New in vitro co-culture model study published with citrus flavonoid extract MicrobiomeX®

MicrobiomeX® is a first-in-class Flavobiotic® developed by BioActor, that combines active ingredients from Citrus sinensis and Citrus paradisi. MicrobiomeX® has already been studied and reported to have various beneficial effects on the gut and immunity. MicrobiomeX® consists of standardised citrus flavonoids, that form active metabolites, hesperetin and naringenin, in the gut after being deglycosylated by the gut microbiota.

In the recently published in-vitro study, a validated co-culture system of Caco-2/THP-1 cells as model for intestinal inflammation and cytokine-induced barrier disruption was used to determine the effects of citrus flavonoids and their metabolites on intestinal inflammation.

During the research, cells were treated with citrus flavonoids, their metabolites, or a vehicle control. Additionally, cells were incubated with lipopolysaccharide (LPS), which is known to induce inflammation and deterioration in epithelial integrity.

The conclusion highlights that hesperetin and naringenin significantly reduced NF-kB activity, leading to a reduction in intestinal inflammation. Pro-inflammatory cytokines IL-8, TNF-α and IL-6 were also significantly reduced after hesperetin and naringenin administration.

The mechanism behind this reduction in inflammation can be ascribed to partial inhibition of the NF-κB signalling pathway.

“We are very happy with the results of this study, as we were able to show that both the citrus flavonoids themselves and their metabolites are able to reduce inflammation in the intestine”, says Yala Stevens, CSO of BioActor. “These new scientific insights on MicrobiomeX® will allow us to consolidate its applications to products targeting gut health and immune function”.

About BioActor

BioActor, based at the Maastricht Health Campus, Netherlands, is a life science company that has developed a range of proprietary bioactive ingredients for the nutrition & consumer health industries. The company focuses on the development of plant-based health ingredients for active living and healthy ageing. The goal is to provide the nutrition & consumer health industries with clinically tested innovations that confer a real health benefit to the consumer.

Feel free to contact BioActor via for more information on the possibilities MicrobiomeX® has to offer.

Further information can be found on: and